For patients with complex chronic wounds that have failed standard care, placental membrane allografts represent one of the most significant advances in wound management over the past two decades. The clinical evidence base has grown substantially, reimbursement pathways are well-established, and the products available today — including completeFT™ — offer multi-layer tissue constructs that closely replicate the biological environment needed for wound closure.

This post covers the biology of placental tissue, what the clinical evidence shows, how completeFT™ is structured and why that matters, and practical considerations for integrating it into a wound care program.

Why Placental Tissue?

The placenta has unique biological properties that make it exceptionally well-suited for wound healing applications. It is immunologically privileged — meaning it does not trigger a significant host immune response when applied to a wound — which allows it to be used as an allograft without the rejection concerns associated with other tissue types.

More importantly, placental tissue is rich in the biological components that drive wound healing: growth factors, cytokines, extracellular matrix proteins, and structural components that support cell migration and tissue regeneration. These are not synthetic additions — they are naturally present in the tissue and are preserved through the processing methods used to prepare clinical-grade allografts.

Key Biological Components

• Growth factors — including EGF, FGF, PDGF, TGF-β, and VEGF — that drive angiogenesis, fibroblast proliferation, and epithelialization
• Extracellular matrix proteins — collagen, fibronectin, laminin — that provide structural scaffolding for cell migration
• Cytokines and anti-inflammatory mediators that modulate the wound environment and reduce chronic inflammation
• Hyaluronic acid, which supports cell proliferation and migration and contributes to a moist wound environment

The completeFT™ Difference: Full-Thickness Multi-Layer Construction

Not all placental allografts are the same. Products vary significantly in their tissue composition, processing methods, and the layers of placental membrane they include. completeFT™ is a full-thickness placental membrane allograft — meaning it includes all three primary layers of the placental membrane: the Amnion, the Intermediate Layer, and the Chorion.

Amnion

The innermost layer of the placental membrane, the amnion is a thin, avascular tissue rich in growth factors and extracellular matrix proteins. It has been the most widely studied layer in wound care applications and is the primary active component in many single-layer amniotic membrane products.

Intermediate Layer

The intermediate layer — sometimes called the spongy layer — sits between the amnion and chorion and contains a loose network of collagen fibers, proteoglycans, and glycoproteins. It contributes to the overall thickness and structural integrity of the graft and provides additional extracellular matrix support.

Chorion

The outermost layer of the placental membrane, the chorion is thicker and more structurally robust than the amnion. It contains a higher density of growth factors and cytokines, including factors that support angiogenesis and modulate inflammation. Including the chorion in the construct significantly increases the biological payload delivered to the wound.

Clinical Evidence

The clinical evidence for placental membrane allografts in chronic wound management is substantial and continues to grow. Key findings from the published literature include:

• Multiple randomized controlled trials demonstrating significantly higher rates of complete wound closure compared to standard care in diabetic foot ulcers
• Prospective studies showing meaningful reductions in wound area and depth in venous leg ulcers
• Retrospective analyses supporting use in pressure injuries, post-surgical wounds, and other complex wound types
• A favorable safety profile with low rates of adverse events across large patient populations

The evidence base has been sufficient to support Medicare coverage under the skin substitute benefit, with established HCPCS coding and reimbursement pathways for outpatient wound care settings.

Patient Selection

completeFT™ is indicated for chronic wounds that have not responded adequately to standard care. The typical candidate profile includes:

• Wound present for 4+ weeks with less than 30% area reduction despite appropriate standard care
• Diabetic foot ulcer (Wagner Grade 1 or 2), venous leg ulcer, or pressure injury (Stage III or IV)
• Adequate wound bed preparation — the wound should be debrided, free of necrotic tissue, and have controlled infection before allograft application
• Adequate perfusion — vascular assessment should confirm sufficient blood flow to support healing
• Patient able to comply with offloading, compression, or other adjunctive care requirements

Practical Application and Reimbursement

completeFT™ is applied in the outpatient wound care setting following standard wound bed preparation. The graft is sized to the wound, applied to the wound bed, and secured with a non-adherent primary dressing and appropriate secondary dressing. Application frequency is typically weekly, with reassessment at each visit to evaluate healing progress.

Reimbursement under Medicare Part B requires documentation of wound type, wound duration, wound measurements, prior treatment history, and the clinical rationale for advanced wound care. Nu Endeavors provides documentation templates and coding support to help wound care centers capture appropriate reimbursement and reduce claim denial risk.